Lord EM - Search Results

1

Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells.

Pulaski BA, Yeh KY, Shastri N, Maltby KM, Penney DP, Lord EM, Frelinger JG. Pulaski BA, et al. Among authors: lord em. Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3669-74. doi: 10.1073/pnas.93.8.3669. Proc Natl Acad Sci U S A. 1996. PMID: 8622994 Free PMC article.

2

Coexpression of IL-2 and gamma-IFN enhances tumor immunity.

McAdam A, Pulaski B, Harkins S, Hutter E, Frelinger J, Lord E. McAdam A, et al. Ann N Y Acad Sci. 1993 Aug 12;690:349-51. doi: 10.1111/j.1749-6632.1993.tb44027.x. Ann N Y Acad Sci. 1993. PMID: 8368753 No abstract available.

3

Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes.

Wei C, Storozynsky E, McAdam AJ, Yeh KY, Tilton BR, Willis RA, Barth RK, Looney RJ, Lord EM, Frelinger JG. Wei C, et al. Among authors: lord em. Cancer Immunol Immunother. 1996 Jul;42(6):362-8. doi: 10.1007/s002620050295. Cancer Immunol Immunother. 1996. PMID: 8830740 Free PMC article.

4

Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy.

Wei C, Willis RA, Tilton BR, Looney RJ, Lord EM, Barth RK, Frelinger JG. Wei C, et al. Among authors: lord em. Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6369-74. doi: 10.1073/pnas.94.12.6369. Proc Natl Acad Sci U S A. 1997. PMID: 9177224 Free PMC article.

5

Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment.

Lee J, Fenton BM, Koch CJ, Frelinger JG, Lord EM. Lee J, et al. Among authors: lord em. Cancer Res. 1998 Apr 1;58(7):1478-85. Cancer Res. 1998. PMID: 9537251

6

Tumor immunotherapy: cytokines and antigen presentation.

Lord EM, Frelinger JG. Lord EM, et al. Cancer Immunol Immunother. 1998 Apr;46(2):75-81. doi: 10.1007/s002620050464. Cancer Immunol Immunother. 1998. PMID: 9558002 Free PMC article. Review.

7

IL-3-mediated enhancement of particulate antigen presentation by macrophages.

Lord EM, Yeh KY, Moran JA, Storozynsky E, Frelinger JG. Lord EM, et al. J Immunother. 1998 May;21(3):205-10. doi: 10.1097/00002371-199805000-00006. J Immunother. 1998. PMID: 9610912

8

IL-3 enhances both presentation of exogenous particulate antigen in association with class I major histocompatibility antigen and generation of primary tumor-specific cytolytic T lymphocytes.

Yeh KY, McAdam AJ, Pulaski BA, Shastri N, Frelinger JG, Lord EM. Yeh KY, et al. Among authors: lord em. J Immunol. 1998 Jun 15;160(12):5773-80. J Immunol. 1998. PMID: 9637487

9

CD4-class II major histocompatibility complex interaction does not enhance killing by a class I-restricted CD4+CD8+ cytotoxic T cell clone.

McAdam AJ, Blieden TM, Frelinger JG, Lord EM. McAdam AJ, et al. Among authors: lord em. Eur J Immunol. 1992 Sep;22(9):2461-4. doi: 10.1002/eji.1830220942. Eur J Immunol. 1992. PMID: 1516633

10

Mechanism of cytolytic T lymphocyte killing of a low class I-expressing tumor.

Blieden TM, McAdam AJ, Frelinger JG, Lord EM. Blieden TM, et al. Among authors: lord em. J Immunol. 1991 Aug 15;147(4):1433-8. J Immunol. 1991. PMID: 1907998

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

197 results

Search Page

Filters